Αρχική World News Prostate Cancer Genomics in Racial Minority Groups

Prostate Cancer Genomics in Racial Minority Groups

Dr. Tamer Khashab of the Baylor College of Medicine in Houston, TX, US reported at 2021 Genitourinary Cancers Symposium real-world findings from the advanced prostate cancer genomics analysis performed in a safety net hospital serving large racial/ethnic minority populations. Dr. Khashab and colleagues observed high frequency of mutations in key prostate cancer drivers that may reflect differences in disease biology between racial/ethnic groups or the more advanced disease presentation due to socioeconomic factors delaying access to health care in African American patients. 

The authors explained in the study background that the largest cancer care disparity in US exists in prostate cancer, with African American men having approximately 1.6 to 1.8 fold higher risk of developing prostate cancer, younger age and more advanced stage at diagnosis, increased risk of recurrence after radical prostatectomy and up to 2.5 fold higher mortality rate relative to men of other ancestries. 

Access to health care and other socioeconomic and environmental factors contribute to the disparity in clinical outcomes. However, genetic factors may also be involved, and their role and prevalence should be better defined, especially in real-world clinical settings, as the high cost of next-generation sequencing (NGS) may have resulted in underrepresentation of uninsured and minority patients in prior studies. 

They retrospectively analyzed NGS data obtained via Tempus | xT tissue assay (DNA sequencing of 648 genes in tumour and matched normal samples at 500x depth) and/or Tempus | xF liquid biopsy assay (ctDNA sequencing of 105 genes in peripheral blood samples at 5,000x depth) for germline and/or somatic mutations detected in 100 patients from whom 53 were African American and who received androgen deprivation therapy for locally advanced, biochemically recurrent or metastatic prostate cancer at Ben Taub Hospital, a safety net hospital in Harris County/Houston serving a patient population of which 91% are racial/ethnic minorities. 

For confirmation, the study team analyzed deidentified NGS data from the US cohort of 1,211 metastatic prostate cancer patients from whom 213 were African American and previously sequenced with xT and/or xF by Tempus Labs. 

The study investigators found higher frequencies of androgen receptor (18.9%), TP53 (41.5%), SPOP (20.7%) and homologous recombination repair (HRR) pathway gene mutations, in particular BRCA2 (17%), in African American cohort at Ben Taub Hospital, as compared to prostate cancer patients of other races/ethnicities. 

The finding was confirmed in the Tempus Labs cohort of patients across US, with 91 of 213 African American patients (42.7%) exhibiting mutation in at least one of 14 HRR pathway genes associated with prostate cancer sensitivity to PARP inhibitors, compared to 347 of 998 non-African American patients (34.7%) (p < 0.05). 

This difference was mainly driven by higher frequency of BRCA2 (16.9%), CDK12 (8%) and PALB2 (5.2%) mutations in African American patients. In both cohorts, TMPRSS2 fusions were much less common in African American prostate cancer patients. 

The authors concluded that their study provides a real-world experience in terms of the genomic analysis of advanced prostate cancer in the clinical setting serving large racial/ethnic minority populations. 

The study results highlight the role of NGS in improving access of such underserved and underrepresented patient populations to treatment with novel targeted therapies and to biomarker-based clinical studies in precision cancer medicine. 

The study was funded by the US National Institutes of Health.

Reference 

Khashab T, Le AD, Cohen S, et al. Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic. J Clin Oncol 2021; 39:(suppl 6; abstr 14). DOI: 10.1200/JCO.2021.39.6_suppl.14.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...